Health-care companies slid after signs of stress in UnitedHealth Group's business.
The largest U.S. insurer by enrollees cut its growth projections, citing hitches with its key Medicare business.
Among other insurers who rely on Medicare demand, Humana shares sold off.
Shares of Eli Lilly soared after the American drug maker's latest glucagon-like peptide pill candidate showed efficacy in a clinical trial on diabetes patients. Investors have long awaited a pill version of the popular obesity-drug injections, and Lilly's pill compared favorably to Novo Nordisk's blockbuster Ozempic product when it came to patients' weight loss.
Shares of Novo Nordisk plunged.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
April 17, 2025 17:16 ET (21:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。